STING1 and STING-associated vasculopathy with onset in infancy: In addition, the novel DMXAA derivative HHMX more strongly antagonized STING pathway activation than DMXAA and became a promising therapeutic agent for STING-associated autoinflammatory diseases, being found to suppress over-functional STING (SAVI mutants)-induced immune responses in vitro, not only in cell lines but also in hPBMCs from SAVI patients, in addition to showing potent therapeutic effects in our SAVI mouse model by mitigating disease progression (Figure 6).